February 09, 2021
We continue our coverage of Longevity Therapeutics 2021 and bring you part 2 of day 1. Dr. Steven Braithwhite - Chief Scientific Officer, Alkahest Steven Braithwhite from Alkahest gave an update on the company’s ongoing clinical trials. Alkahest has been sifting plasma proteome in search for proteins that decrease or increase with age. The company calls...
November 12, 2020
A team of researchers, including Dr. Tony Wyss-Coray, co-founder of Alkahest, has discovered that exposing young cells to aged blood makes their gene expression like old cells. Signaling cells to act older We have known from the heterochronic parabiosis and plasmapheresis research performed by Dr. Irina Conboy's lab and similar work done by Dr. Wyss-Coray's...
June 03, 2020
Alkahest has announced plans to launch a Phase 2 clinical trial that aims to address cognitive impairment and takes the unusual approach of using an external medical device that filters a harmful protein from the blood of end-stage renal disease patients. The medical device, known as an AKST1210, will be connected in-line with a haemodialysis...